Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Orion Pharma's Enterprise Value is BDT35,508 Mil.
Orion Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-143 Mil. Therefore, Orion Pharma's EV-to-EBIT ratio for today is -247.56.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Orion Pharma's Enterprise Value is BDT35,508 Mil.
Orion Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT433 Mil. Therefore, Orion Pharma's EV-to-EBITDA ratio for today is 82.08.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Orion Pharma's Enterprise Value is BDT35,508 Mil.
Orion Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was BDT3,759 Mil. Therefore, Orion Pharma's EV-to-Revenue ratio for today is 9.45.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Orion Pharma's Enterprise Value is BDT35,508 Mil.
Orion Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT401 Mil. Therefore, Orion Pharma's EV-to-FCF ratio for today is 88.59.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Orion Pharma (DHA:ORIONPHARM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Orion Pharma's current Enterprise Value is BDT35,508 Mil.
Orion Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-143 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Orion Pharma's current Enterprise Value is BDT35,508 Mil.
Orion Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT433 Mil.
Orion Pharma's current Enterprise Value is BDT35,508 Mil.
Orion Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT3,759 Mil.
Orion Pharma's current Enterprise Value is BDT35,508 Mil.
Orion Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT822 Mil.
Orion Pharma's current Enterprise Value is BDT35,508 Mil.
Orion Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT401 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma Enterprise Value Related Terms
Orion Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Enterprise Value Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Enterprise Value vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Orion Pharma's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of BDT35,508 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Enterprise Value of BDT35,508 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Enterprise Value too high?
Orion Pharma's current Enterprise Value is BDT35,508 Mil. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Enterprise Value compare to CEG and VST?
Orion Pharma's Enterprise Value of BDT35,508 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for an Utilities - Independent Power Producers company?
A good Enterprise Value depends on the Utilities - Independent Power Producers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orion Pharma and its competitors. Orion Pharma's current Enterprise Value is BDT35,508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current Enterprise Value is BDT35,508 Mil. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Enterprise Value is BDT35,508 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Enterprise Value: BDT35,508 Mil
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
